Fampridine-SR for multiple sclerosis and spinal cord injury

References

• Waxman SG. Multiple Sclerosis as a Neuronal Disease. Elsevier Academic Press, Amsterdam, The Netherlands (2005).
   Google Scholar
• Bunge RP, Puckett WR, Becerra JL, Marcillo A, Quencer RM. Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. In: Advances in Neurology. Seil FJ (Ed.). Raven Press, NY, USA (1993).
   Google Scholar
• Guest JD, Hiester ED, Bunge RP. Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp. Neurol.192(2), 384–393 (2005).
   PubMedGoogle Scholar
• Totoiu MO,Keirstead HS. Spinal cord injury is accompanied by chronic progressive demyelination. J. Comp. Neurol.486(4), 373–383 (2005).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Waxman SG. The conduction properties of demyelinated and remyelinated axons. In: Multiple Sclerosis as a Neuronal Disease. Waxman S (Ed.). Elsevier Academic Press, Amsterdam, The Netherlands (2005).
   Google Scholar
• Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci.3(4), 291–301 (2002).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol.12(3), 295–302 (1999).
   PubMed Web of Science ®Google Scholar
• Tasaki I. Nervous Transmission. Charles C (Ed.). Thomas, Springfield, IL, USA (1953).
   Google Scholar
• Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res. Bull.22(1), 47–52 (1989).
   PubMed Web of Science ®Google Scholar
• Bostock H, Sherratt RM, Sears TA. Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature274, 385–387 (1978).
   PubMed Web of Science ®Google Scholar
• Bowe CM, Kocsis JD, Targ EF, Waxman SG. Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann. Neurol.22(2), 264–268 (1987).
   PubMedGoogle Scholar
• Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyiridine on normal and demyelinated mammalian nerve fibres. Nature283(7), 570–572 (1980).
   PubMed Web of Science ®Google Scholar
• Targ EF, Kocsis JD. 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res.328, 358–361 (1985).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr. 4-Aminopyridine: use in multiple sclerosis. CNS Drug Rev.1(2), 261–279 (1995).
   Google Scholar
• Hayes KC. 4-Aminopyridine and spinal cord injury: a review. Rest. Neurol. Neurosci.6, 259–270 (1994).
   PubMedGoogle Scholar
• Bever CT Jr, Young D, Anderson PA et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology44(6), 1054–1059 (1994).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Katz E, Tierney D, Johnson K. Experience with slow release 4-aminopyridine in multiple sclerosis patients: Long term tolerability and safety. J. Neuroimmunol.1(Suppl.), 58 (1995).
   Google Scholar
• Hayes KC, Potter PJ, Hansebout RR et al. Pharmacokinetic studies of single and multiple oral doses of Fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clin. Neuropharmacol.26(4), 185–192 (2003).
   PubMed Web of Science ®Google Scholar
• Compston A,Coles A. Multiple sclerosis. Lancet359(9313), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain112(Pt 1), 133–146 (1989).
   PubMed Web of Science ®Google Scholar
• Pickett GE, Campos-Benitez M, Keller JL, Duggal N. Epidemiology of traumatic spinal cord injury in Canada. Spine31(7), 799–805 (2006).
   PubMed Web of Science ®Google Scholar
• Wyndaele M,Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord44(9), 523–529 (2006).
   PubMed Web of Science ®Google Scholar
• Burks J. Interferon-β1b for multiple sclerosis. Expert Rev. Neurother.5(2), 153–164 (2005).
   PubMedGoogle Scholar
• Emery E, Aldana P, Bunge MB et al. Apoptosis after traumatic human spinal cord injury. J. Neurosurg.89(6), 911–920 (1998).
   PubMed Web of Science ®Google Scholar
• Griffiths IR, McCulloch MC. Nerve fibres in spinal cord impact injuries. Part 1. Changes in the myelin sheath during the initial 5 weeks. J. Neurol. Sci.58(3), 335–349 (1983).
   PubMedGoogle Scholar
• Gledhill RF, Harrison BM, McDonald WI. Demyelination and remyelination after acute spinal cord compression. Exp. Neurol.38(3), 472–487 (1973).
   PubMedGoogle Scholar
• Harrison BM, McDonald WI. Remyelination after transient experimental compression of the spinal cord. Ann. Neurol.1(6), 542–551 (1977).
   PubMedGoogle Scholar
• Salgado-Ceballos H, Guizar-Sahagun G, Feria-Velasco A et al. Spontaneous long-term remyelination after traumatic spinal cord injury in rats. Brain Res.782(1–2), 126–135 (1998).
   PubMed Web of Science ®Google Scholar
• Chiu SY. The roles of potassium and calcium channels in physiology and pathophysiology of axons. In: Multiple Sclerosis as a Neuronal Disease. Waxman S (Ed.). Elsevier Academic Press, Amsterdam, The Netherlands (2005).
   Google Scholar
• Waxman SG, Kocsis JD, Stys PK. The Axon: Structure, Function and Pathophysiology. Oxford University Press, New York, USA (1995).
   Google Scholar
• Reid G, Scholz A, Bostock H, Vogel W. Human axons contain at least five types of voltage-dependent potassium channel. J. Physiol.518(Pt 3), 681–696 (1999).
   PubMed Web of Science ®Google Scholar
• Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol. Ther.111(1), 224–259 (2006).
   PubMed Web of Science ®Google Scholar
• Hille B. Ionic Channels in Excitable Membranes. Sinauer Associates, Sunderland, MA, USA (2001).
   Google Scholar
• Stuhmer W, Ruppersberg JP, Schroter KH et al. Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain. EMBO J.8(11), 3235–3244 (1989).
   PubMed Web of Science ®Google Scholar
• Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J. Physiol.313, 301–315 (1981).
   PubMed Web of Science ®Google Scholar
• Kim YI, Goldner MM, Sanders DB. Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission. Muscle Nerve3(2), 105–111 (1980).
   PubMedGoogle Scholar
• Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res.153, 307–318 (1978).
   PubMed Web of Science ®Google Scholar
• Molgo J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Clin. Pharmacol.61, 25–34 (1980).
   Google Scholar
• Kim YI, Goldner MM, Sanders DB. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve3(2), 112–119 (1980).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain123(Pt 1), 171–184 (2000).
   PubMed Web of Science ®Google Scholar
• Paskov DS, Agoston S, Bowman WC. 4-aminopyridine hydrochloride (Pymadin). New neuromuscluar blocking agents – basic and applied aspects. In: Handbook of Experimental Pharmacology. Charkavich DA (Ed.). Springer-Verlag (1986).
   Google Scholar
• Davis FA, Stefoski D, Quandt FN. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann. Neurol.37(5), 684 (1995).
   PubMed Web of Science ®Google Scholar
• Felts PA, Smith KJ. The use of potassium channel blocking agents in the therapy of demyelinating diseases. Ann. Neurol.36(3), 454 (1994).
   PubMed Web of Science ®Google Scholar
• Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience77(2), 553–562 (1997).
   PubMed Web of Science ®Google Scholar
• Perry VH, Phil D. Inflammation and axon degeneration. In: Multiple Sclerosis as a Neuronal Disease. Waxman S (Ed.). Elsevier Academic Press, Amsterdam, The Netherlands (2005).
   Google Scholar
• Devaux J, Beeton C, Beraud E, Crest M. Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers. Rev. Neurol. (Paris)160(5 Pt 2), S16–S27 (2004).
   PubMed Web of Science ®Google Scholar
• Judge SI, Lee JM, Bever CT Jr, Hoffman PM. Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J. Rehabil. Res. Dev.43(1), 111–122 (2006).
   PubMed Web of Science ®Google Scholar
• Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Devel.6(5), 640–647 (2003).
   PubMedGoogle Scholar
• Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol.27(2), 186–192 (1990).
   PubMed Web of Science ®Google Scholar
• Stefoski D, Davis FA, Fitzsimmons WE et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology41, 1344–1348 (1991).
   PubMed Web of Science ®Google Scholar
• Evenhuis J, Agoston S, Salt PJ et al. Pharmacokinetics of 4-aminopyridine in human volunteers: a preliminary study using a new GLC method for its estimation. Br. J. Anaesth.53, 567–570 (1981).
   PubMed Web of Science ®Google Scholar
• Hayes KC, Katz MA, Devane JG et al. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J. Clin. Pharmacol43(4), 379–385 (2003).
   PubMed Web of Science ®Google Scholar
• Uges DRA, Sohn YJ, Greijdanus B, Scaf AHJ, Agoston S. 4-aminopyridine kinetics. Clin. Pharmacol. Ther.31(5), 587–593 (1982).
   PubMed Web of Science ®Google Scholar
• Lemeignan M, Millart H, Lamiable D, Molgo J, Lechat P. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res.304(1), 166–169 (1984).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Young D, Tierney D et al. The pharmacokinetics and tolerability of a slow-release formulation of 4-aminopyridine in multiple sclerosis patients. Neurology45(Suppl. 4), A351 (1995).
   Google Scholar
• Segal JL, Hayes KC, Brunnemann SR et al. Absorption characteristics of sustained-release 4-aminopyridine (Fampridine SR) in patients with chronic spinal cord injury. J. Clin. Pharmacol.40(4), 402–409 (2000).
   PubMed Web of Science ®Google Scholar
• Hayes KC, Potter PJ, Hsieh JT et al. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch. Phys. Med. Rehabil.85, 29–34 (2004).
   PubMed Web of Science ®Google Scholar
• van Diemen HA, Polman CH, van Dongen MM et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J. Neurol. Sci.116(2), 220–226 (1993).
   PubMed Web of Science ®Google Scholar
• Johnson NC,Morgan MW. An unusual case of 4-aminopyridine toxicity. J. Emerg. Med.30(2), 175–177 (2006).
   PubMed Web of Science ®Google Scholar
• Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder. Ned. Tijdschr. Geneeskd.139(51), 2667–2669 (1995).
   PubMedGoogle Scholar
• Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin. Toxicol.16(4), 487–497 (1980).
   PubMed Web of Science ®Google Scholar
• Velez L, Shirazi F, Goto C, Shepherd G, Roth BA. Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient. Pediatrics111(1), E82–E84 (2003).
   PubMed Web of Science ®Google Scholar
• Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J. Toxicol. Clin. Toxicol.32(5), 583–587 (1994).
   PubMed Web of Science ®Google Scholar
• Pickett TA, Enns R. Atypical presentation of 4-aminopyridine overdose. Ann. Emerg. Med.27(3), 382–385 (1996).
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen J, Vollmer T et al. Phase 2 trial of Fampridine-SR in multiple sclerosis. Mult. Scler.10(Suppl. 2), P695 (2004).
   Google Scholar
• Schwid SR, Petrie MD, McDermott MP et al. Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology48, 817–821 (1997).
   PubMed Web of Science ®Google Scholar
• Hayes KC. The use of 4-aminopyridine (Fampridine) in demyelinating disease. CNS Drug Rev.10(4), 295–316 (2004).
   PubMedGoogle Scholar
• Goodman AD, Blight A, Cohen JA et al. Placebo-controlled double-blinded dose ranging study of Fampridine-SR in multiple sclerosis. Neurology60(Suppl. 1), A167 (2003).
   Google Scholar
• Potter PJ, Hayes KC, Segal JL et al. Randomized double-blind crossover trial of Fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J. Neurotrauma15(10), 837–849 (1998).
   PubMed Web of Science ®Google Scholar
• Ditunno JF Jr, Graziani V, Katz MA, Blight AR, Group S-S. Double-blind, placebo-controlled, dose-escalating study evaluating the safety and efficacy of oral doses of Fampridine-SR (sustained-release 4-aminopyridine) in patinets with chronic spinal cord injury. J. Spinal Cord. Med.25, S1–S38 (2002).
   PubMedGoogle Scholar
• Cardenas DD, Ditunno J, Graziani V et al. Phase 2 trial of sustained-release Fampridine in chronic spinal cord injury. Spinal Cord45(2), 158–168 (2007).
   PubMed Web of Science ®Google Scholar
• McBride JM, Smith DT, Byrn SR, Borgens RB, Shi R. Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma. Eur. J. Pharm. Sci.27(2–3), 237–242 (2006).
   PubMedGoogle Scholar
• Smith DT, Shi R, Borgens RB et al. Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease. Eur. J. Med. Chem.40(9), 908–917 (2005).
   PubMedGoogle Scholar
• Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. The safety and efficacy of 4-aminopyridine for motor weakness due to Guillain–Barré Syndrome: a double-blind cross-over Phase I drug trial. Arch. Phys. Med. Rehabil.81, 1293 (2000).
   Google Scholar
• Glasauer S, Kalla R, Buttner U, Strupp M, Brandt T. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus. J. Neurol. Neurosurg. Psychiatry76(3), 451–453 (2005).
   PubMed Web of Science ®Google Scholar
• Rucker JC. Current treatment of nystagmus. Curr. Treat. Options. Neurol.7(1), 69–77 (2005).
   PubMedGoogle Scholar
• Strupp M, Kalla R, Dichgans M et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology62(9), 1623–1625 (2004).
   PubMed Web of Science ®Google Scholar
• Weisz CJ, Raike RS, Soria-Jasso LE, Hess EJ. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J. Neurosci.25(16), 4141–4145 (2005).
   PubMed Web of Science ®Google Scholar
• Halter JA, Blight AR, Donovan WH, Calvillo O. Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. Spinal Cord38(12), 728–732 (2000).
   PubMedGoogle Scholar
• Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev.52(4), 557–594 (2000).
   PubMed Web of Science ®Google Scholar
• Wickenden A. K+ channels as therapeutic drug targets. Pharmacol. Ther.94(1–2), 157–182 (2002).
   PubMed Web of Science ®Google Scholar
• Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst. Rev. (2), CD001330 (2003).
   Google Scholar